Growth • Neurocrine Biosciences
NBIX
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
24,5%
CAGR Revenue 5Y
Revenue Compound Annual Growth Rate in the last 5 years.
20,8%
CAGR Op. Income 5Y
Operating Income Compound Annual Growth Rate in the last 5 years.
55,9%
CAGR Net Income 5Y
Net Income Compound Annual Growth Rate in the last 5 years.
53,2%
CAGR EPS 5Y
Earnings Per Share Compound Annual Growth Rate in the last 5 years.
18%
CAGR Normalized EPS 5Y
Normalized Earnings Per Share Compound Annual Growth Rate in the last 5 years.
31,4%
CAGR OCF 5Y
Cash Flow from Operating activities Compound Annual Growth Rate in the last 5 years.
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!